Last updated: April 26, 2026
Lidocaine hydrochloride preservative-free product supply is typically sourced through (1) finished-dose sterile injectables and (2) licensed sterile manufacturing of preservative-free lidocaine hydrochloride packaged in plastic containers (commonly single-dose/PL or prefilled formats). Supplier identification depends on the exact presentation (strength, volume, container type, and whether it is USP <797> compliant sterile injectable or for local anesthesia use), because preservative-free lidocaine is a constrained SKU family versus multi-dose, benzyl alcohol-containing equivalents.
What supplier channels provide preservative-free lidocaine in plastic containers?
1) US drug manufacturers of sterile lidocaine hydrochloride injection (preservative-free)
Common supply routes include FDA-licensed sterile injectables manufacturers that produce:
- Lidocaine hydrochloride injection, preservative-free (single-dose formats)
- Lidocaine hydrochloride injection packaged in plastic containers (depending on presentation)
2) Specialty wholesalers and distributors
Wholesalers do not manufacture but control inventory depth and allocation during intermittent supply conditions. They can be the fastest path to available lots for hospitals, ambulatory centers, and wholesalers’ managed accounts.
3) Contract sterile manufacturing and packaging networks
Some firms supply preservative-free sterile drug substance and finished sterile fill-finish under private label or through branded distributors. This route matters when a product is re-labeled by multiple suppliers but originates from a single sterile manufacturing platform.
Which suppliers are most commonly positioned to supply this SKU family?
The specific product title provided (“LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER”) aligns to preservative-free sterile lidocaine injection presentations that are widely distributed in the US. In practice, procurement usually maps to a short set of recurring supplier/distributor names that carry preservative-free lidocaine across hospitals and group purchasing organizations (GPOs).
Manufacturer and label-holder candidates (US market positioning)
These firms are consistently present in the lidocaine injection ecosystem through branded products, authorized generics, and contract manufacturing-linked private label offerings:
- Hospira (Pfizer) / Pfizer branded legacy sterile products
- Teva Pharmaceuticals
- Sagent / Fresenius Kabi ecosystem for sterile injectables
- B. Braun
- Piramal / Medline or re-labeled sterile injectable networks (varies by presentation)
Distributor and wholesaler candidates (procurement availability)
These companies are structurally positioned to offer fast ordering, lot traceability, and substitute options when preservative-free lidocaine is constrained:
- McKesson
- Cardinal Health
- AmerisourceBergen
GPO-linked distribution (institutional procurement)
For hospital procurement, GPO leverage typically determines whether you see “available with allocation” versus “backordered,” even when multiple manufacturers exist. The most operationally relevant GPO-distributor pathways in the US tend to be McKesson, Cardinal, and AmerisourceBergen.
What product attributes must match for true “preservative-free in plastic container” supply?
For procurement and substitution control, you need exact alignment on the following attributes:
| Attribute |
What to verify on the label/IFU |
Why it matters |
| Preservative status |
“Preservative-free” / “without preservative” |
Multi-dose lidocaine often contains preservatives such as benzyl alcohol; substituting changes risk profile |
| Strength |
e.g., 1% (10 mg/mL), 2% (20 mg/mL), or other |
Clinical dosing and concentration-specific use |
| Total volume and container format |
single-dose volume, prefilled syringe vs vial vs bag-in-plastic |
Controls dosing workflow and waste |
| Container type |
“plastic container” (presentation-specific) |
Packaging affects availability and compatibility requirements |
| Sterility and route |
“sterile,” injection route labeling |
Prevents improper substitution across routes |
| Needleless administration compatibility |
if used for prefilled syringes |
Impacts hospital nursing and administration processes |
How to map suppliers to a procurement-ready list (operational view)
A procurement-ready supplier list is usually built by separating “manufacturer/label-holder” from “distributor who can source lots quickly.”
Procurement supplier stack
- Primary distributors (ship-to availability)
- McKesson
- Cardinal Health
- AmerisourceBergen
- Manufacturer/label-holder
- Pfizer (Hospira legacy positioning)
- Teva
- B. Braun
- Fresenius Kabi-related sterile injectable platforms
- Institutional pathways
- GPO contract distributor (often one of the three above)
- Alternate distributor only if the primary allocation is hit
What substitution risk shows up for preservative-free lidocaine?
The substitution risk is not theoretical. The most common failure modes in pharmacy substitution programs are:
- Substituting preservative-free lidocaine with multi-dose lidocaine containing benzyl alcohol
- Substituting non-plastic container presentations (glass vial) when an order requires plastic-container compatibility
- Substituting strength or volume without matching units (percent vs mg/mL and total dose)
Procurement controls that prevent these errors are typically tied to:
- National Drug Codes (NDC) and label text matching
- Purchasing item number matching
- Dose-range guardrails (concentration and total volume)
- Packaging specification matching (“plastic container” requirement)
What supplier-selection logic improves continuity of supply?
Prioritize distributor coverage plus manufacturer redundancy
A durable sourcing strategy uses:
- Multiple distribution channels (within the same GPO umbrella when possible)
- Multiple manufacturer/label-holder candidates for the same NDC-equivalent product family
Prefer inventory-managed contracts for high-use presentations
For high-throughput sites (ED, OR, anesthesia), contract and safety stock drive availability more than list price.
Supplier list (actionable shortlist for procurement workflows)
Wholesalers/distributors to request availability and allocation status
- McKesson
- Cardinal Health
- AmerisourceBergen
Manufacturer/label-holder categories to request equivalent preservative-free, plastic-container presentations from
- Pfizer (Hospira legacy sterile injection platform)
- Teva
- B. Braun
- Fresenius Kabi sterile injectable platforms
- Private-label/contract-manufactured sterile injectable networks (varies by presentation)
Key procurement checklist for “preservative-free in plastic container” orders
Use this checklist when placing purchase orders and verifying receipt:
- Confirm label states: “preservative-free”
- Confirm concentration (percent and mg/mL)
- Confirm container type is plastic (not glass vial)
- Confirm total volume and format (prefilled syringe vs single-dose vial in plastic packaging)
- Record NDC and lot number
- Confirm compatibility with your administration workflow (especially for OR/anesthesia automation)
Key Takeaways
- Supply for “lidocaine hydrochloride preservative-free in plastic container” is anchored in sterile injectable manufacturing plus GPO-influenced distribution.
- The most operationally relevant supplier touchpoints are McKesson, Cardinal Health, and AmerisourceBergen for inventory and allocation.
- Manufacturer candidates to request equivalents from are Pfizer (Hospira legacy), Teva, B. Braun, and Fresenius Kabi sterile injectable platforms.
- Substitution errors most commonly come from preservative status, concentration, and container format mismatches; NDC and label-text matching are the control points.
FAQs
1) What is the most common reason preservative-free lidocaine substitution fails?
Preservative status mismatch (multi-dose lidocaine with benzyl alcohol substituted for preservative-free).
2) Does “plastic container” always mean a prefilled syringe?
No. “Plastic container” is presentation-specific. You must verify the product’s labeled container format.
3) Which distributors usually provide the fastest allocation visibility?
McKesson, Cardinal Health, and AmerisourceBergen typically provide the most direct allocation and on-hand visibility to institutional buyers.
4) Can I treat preservative-free lidocaine as interchangeable with lidocaine injection in general?
No. Preservative-free is a distinct SKU family. Concentration and container format also must match.
5) What document fields should procurement lock to prevent errors?
NDC, concentration (percent and mg/mL), total volume, preservative-free wording, container type, and lot traceability.
References (APA)
[1] FDA. (n.d.). Drug shortages: Lidocaine hydrochloride injection (searchable by active ingredient and dosage form). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/drugshortages/
[2] FDA. (n.d.). Drugs@FDA (search by active ingredient and applicant to identify approved products and label information). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] FDA. (n.d.). NDC directory (to map NDCs to finished products and packaging). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
